AbbVie's Allergan Files US Application AGN-190584 For Presbyopia

  • Allergan, an AbbVie Inc (NYSE: ABBV), has submitted a marketing application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the application by the end of 2021.
  • Presbyopia is a common and progressive eye condition that reduces the eye's ability to focus on near objects and usually impacts people after age 40.
  • AGN-190584 is an investigational optimized formulation of pilocarpine, a cholinergic muscarinic receptor agonist, which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle.
  • Price Action: ABBV is down 0.95% at $107.66 in market trading hours on the last check Thursday.
Posted In: presbyopiaBiotechNewsHealth CareFDAGeneral